Literature DB >> 28529917

Current guidelines on prevention with a focus on dyslipidemias.

Ian M Graham1,2, Alberico L Catapano3, Nathan D Wong4.   

Abstract

Examination of the current the American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines on the prevention of cardiovascular disease and the management of dyslipidemias finds much common ground. Both note that Atherosclerotic cardiovascular disease (ASCVD) is, in most people, the product of a number of risk factors, notably tobacco exposure, hyperlipidemia, hypertension, inactivity, overweight and diabetes. They stress that risk calculators can help in the assessment of risk in apparently healthy persons. Persons with established ASCVD and many with diabetes or renal impairment are at high to very high risk and warrant intensive risk factor advice and guideline-based preventive therapies. The ACC/AHA guidelines favor the universal use of statins in all high-risk subjects and in primary prevention where the global risk exceeds 7.5% in 10 years, with a percentage reduction in low-density lipoprotein cholesterol (LDL-C) based on statin intensity as the "goal". In contrast, the ESC/EAS guidelines favor a goal or percentage-based reduction in LDL-C based on total risk and baseline LDL-C level. Both guidelines consider certain imaging and other measures to stratify risk as well as the use of non-statin therapies in those not achieving recommended targets. Perhaps the most important challenges are to stress similarities rather than differences, and to simplify communications with both healthcare professionals and the public.

Entities:  

Keywords:  Atherosclerotic cardiovascular disease (ASCVD); cardiovascular risk; cholesterol; low-density lipoprotein cholesterol (LDL-C); risk factors

Year:  2017        PMID: 28529917      PMCID: PMC5418212          DOI: 10.21037/cdt.2017.04.04

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  22 in total

1.  More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines.

Authors:  John P A Ioannidis
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

2.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

3.  2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Robert H Eckel; John M Jakicic; Jamy D Ard; Janet M de Jesus; Nancy Houston Miller; Van S Hubbard; I-Min Lee; Alice H Lichtenstein; Catherine M Loria; Barbara E Millen; Cathy A Nonas; Frank M Sacks; Sidney C Smith; Laura P Svetkey; Thomas A Wadden; Susan Z Yanovski; Karima A Kendall; Laura C Morgan; Michael G Trisolini; George Velasco; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

4.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.

Authors:  Michael D Jensen; Donna H Ryan; Caroline M Apovian; Jamy D Ard; Anthony G Comuzzie; Karen A Donato; Frank B Hu; Van S Hubbard; John M Jakicic; Robert F Kushner; Catherine M Loria; Barbara E Millen; Cathy A Nonas; F Xavier Pi-Sunyer; June Stevens; Victor J Stevens; Thomas A Wadden; Bruce M Wolfe; Susan Z Yanovski; Harmon S Jordan; Karima A Kendall; Linda J Lux; Roycelynn Mentor-Marcel; Laura C Morgan; Michael G Trisolini; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

5.  Cardiovascular risk age: concepts and practicalities.

Authors:  Marie Therese Cooney; Erkki Vartiainen; Tiina Laatikainen; Dirk De Bacquer; Catherine McGorrian; Alexandra Dudina; Ian Graham
Journal:  Heart       Date:  2012-06       Impact factor: 5.994

6.  Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.

Authors:  Michael A Blazing; Robert P Giugliano; Christopher P Cannon; Thomas A Musliner; Andrew M Tershakovec; Jennifer A White; Craig Reist; Amy McCagg; Eugene Braunwald; Robert M Califf
Journal:  Am Heart J       Date:  2014-05-15       Impact factor: 4.749

7.  Statins for millions more?

Authors: 
Journal:  Lancet       Date:  2014-02-22       Impact factor: 79.321

8.  2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno
Journal:  Eur Heart J       Date:  2016-05-23       Impact factor: 29.983

9.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

Review 10.  Overview of guidelines for the management of dyslipidemia: EU perspectives.

Authors:  Vicente Giner-Galvañ; María José Esteban-Giner; Vicente Pallarés-Carratalá
Journal:  Vasc Health Risk Manag       Date:  2016-09-06
View more
  4 in total

1.  Therapeutic effects of statins on chromosomal DNA damage of dyslipidemic patients.

Authors:  Hamiyet Donmez-Altuntas; Fahri Bayram; Ayse N Coskun-Demirkalp; Osman Baspınar; Derya Kocer; Peter P Toth
Journal:  Exp Biol Med (Maywood)       Date:  2019-08-19

2.  Attenuation of atherogenic apo B-48-dependent hyperlipidemia and high density lipoprotein remodeling induced by vitamin C and E combination and their beneficial effect on lethal ischemic heart disease in mice.

Authors:  S Contreras-Duarte; P Chen; M Andía; S Uribe; P Irarrázaval; S Kopp; S Kern; G Marsche; D Busso; C Wadsack; A Rigotti
Journal:  Biol Res       Date:  2018-09-15       Impact factor: 5.612

3.  MDG-1, a Potential Regulator of PPARα and PPARγ, Ameliorates Dyslipidemia in Mice.

Authors:  Xu Wang; Linlin Shi; Sun Joyce; Yuan Wang; Yi Feng
Journal:  Int J Mol Sci       Date:  2017-09-08       Impact factor: 5.923

4.  Association between the PLTP rs4810479 SNP and Serum Lipid Traits in the Chinese Maonan and Han Populations.

Authors:  Fen-Han Zhang; Rui-Xing Yin; Li-Mei Yao; Wei-Xiong Lin; Jin-Zhen Wu; De-Zhai Yang
Journal:  Genet Res (Camb)       Date:  2021-07-02       Impact factor: 1.588

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.